DZIF-10c is a fully human monoclonal neutralizing antibody that
targets the receptor-binding domain of the SARS-CoV-2 spike protein
and powerfully blocks the original virus as well as the B.1.1.7
variant (and, with lower potency, B.1.351). In mice, both systemic
and intranasal dosing cleared infectious virus from the lungs,
reduced lung pathology, and—thanks to a favorable pharmacokinetic
profile—positions DZIF-10c as a promising prophylactic or
therapeutic antibody that could be delivered topically via the
nose.
Pharmacokinetics
parameteres estimated from [1] and dosage 40 g
References
1. Halwe,
S., Kupke, A., Vanshylla, K., Liberta, F., Gruell, H., Zehner, M.,
Rohde, C., Krähling, V., Gellhorn Serra, M., Kreer, C., Klüver, M.,
Sauerhering, L., Schmidt, J., Cai, Z., Han, F., Young, D., Yang,
G., Widera, M., Koch, M., ... Becker, S. (2021). Intranasal
Administration of a Monoclonal Neutralizing Antibody Protects Mice
against SARS-CoV-2 Infection. Viruses, 13(8),
1498. DOI:
10.3390/v13081498
- 06/2025
Tomas Kulhanek, initial version to fit reported data
Generated at 2026-04-15T18:18:36Z by OpenModelicaOpenModelica 1.26.3 using
GenerateDoc.mos
.Pharmacolibrary.Drugs.Z_Unclassified.J06B_ProbableImmunoglobulins.DZIF10c.DZIF10c_1C